JournalsHub
.online
Find My Journal
RR

Reinhard von Roemeling

Independent Researcher

109
Publications
3,029
Citations
26
H-Index
46
i10-Index
1.0
2yr Mean Cite
-
Cite/Paper
Data combined from OpenAlex . OA = OpenAlex S2 = Semantic Scholar
Verify on Google Scholar

Publication & Citation Trends

Most Cited Works

Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
Armando Santoro, Lorenza Rimassa, Ivan Borbath, Bruno Daniele, Stefania Salvagni +23 more
The Lancet Oncology 2012
550
Tirapazamine Plus Cisplatin Versus Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Report of the International CATAPULT I Study Group
Joachim von Pawel, Reinhard von Roemeling, U. Gatzemeier, Michael Boyer, Lars Ove Elisson +14 more
Journal of Clinical Oncology 2000
286
Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non–Small-Cell Lung Cancer OA
Giorgio V. Scagliotti, Joachim von Pawel, Silvia Novello, Rodryg Ramlau, Adolfo Favaretto +14 more
Journal of Clinical Oncology 2015
260
Phase I Trial of Concurrent Tirapazamine, Cisplatin, and Radiotherapy in Patients With Advanced Head and Neck Cancer
Danny Rischin, Lester Peters, Rodney J. Hicks, Peter Hughes, Richard Fisher +4 more
Journal of Clinical Oncology 2001
202
Rationale and Design of MARQUEE: A Phase III, Randomized, Double-Blind Study of Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Patients With Locally Advanced or Metastatic, Nonsquamous, Non–Small-Cell Lung Cancer OA
Giorgio V. Scagliotti, Silvia Novello, Joan H. Schiller, Vera Hirsh, Lecia V. Sequist +5 more
Clinical Lung Cancer 2012
126

Publications

109 total

A randomized, placebo‐controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild‐type <i>KRAS</i> who have received first‐line systemic therapy PDF

Cathy Eng, Alberto Bessudo, Lowell L. Hart, A. Severtsev, Oleg Gladkov et al. - International Journal of Cancer, 2016
Cited by 68 OpenAlex

Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non–Small-Cell Lung Cancer PDF

Giorgio V. Scagliotti, Joachim von Pawel, Silvia Novello, Rodryg Ramlau, Adolfo Favaretto et al. - Journal of Clinical Oncology, 2015
Cited by 260 OpenAlex

Efatutazone, an Oral PPAR-γ Agonist, in Combination With Paclitaxel in Anaplastic Thyroid Cancer: Results of a Multicenter Phase 1 Trial PDF

Robert C. Smallridge, John A. Copland, Marcia S. Brose, J. Trad Wadsworth, Yariv Houvras et al. - The Journal of Clinical Endocrinology & Metabolism, 2013
Cited by 113 OpenAlex

Phase 2, multicenter, open‐label study of tigatuzumab (CS‐1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy‐naive patients with unresectable or metastatic pancreatic cancer PDF

Andres Forero‐Torres, Jeffrey R. Infante, David Waterhouse, Lucas Wong, Selwyn M. Vickers et al. - Cancer Medicine, 2013
Cited by 90 OpenAlex

Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study

Armando Santoro, Lorenza Rimassa, Ivan Borbath, Bruno Daniele, Stefania Salvagni et al. - The Lancet Oncology, 2012
Cited by 550 OpenAlex

Rationale and Design of MARQUEE: A Phase III, Randomized, Double-Blind Study of Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Patients With Locally Advanced or Metastatic, Nonsquamous, Non–Small-Cell Lung Cancer PDF

Giorgio V. Scagliotti, Silvia Novello, Joan H. Schiller, Vera Hirsh, Lecia V. Sequist et al. - Clinical Lung Cancer, 2012
Cited by 126 OpenAlex

Phase I Trial of Concurrent Tirapazamine, Cisplatin, and Radiotherapy in Patients With Advanced Head and Neck Cancer

Danny Rischin, Lester Peters, Rodney J. Hicks, Peter Hughes, Richard Fisher et al. - Journal of Clinical Oncology, 2001
Cited by 202 OpenAlex

Tirapazamine Plus Cisplatin Versus Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Report of the International CATAPULT I Study Group

Joachim von Pawel, Reinhard von Roemeling, U. Gatzemeier, Michael Boyer, Lars Ove Elisson et al. - Journal of Clinical Oncology, 2000
Cited by 286 OpenAlex

Concurrent tirapazamine and radiotherapy for advanced head and neck carcinomas: a phase II study PDF

Ding‐Jen Lee, Andy Trotti, Sharon A. Spencer, Robert A. Rostock, Cheryl Fisher et al. - International Journal of Radiation Oncology*Biology*Physics, 1998
Cited by 82 OpenAlex

Tirapazamine with cisplatin in patients with advanced non-small-cell lung cancer: a phase II study.

J. Treat, Eugene H. Johnson, Corey J. Langer, Chandra P. Belani, Benjamin P. Haynes et al. - Journal of Clinical Oncology, 1998
Cited by 64 OpenAlex

Research Topics

Radiopharmaceutical Chemistry and Applications (11) Cancer therapeutics and mechanisms (10) Acute Myeloid Leukemia Research (9) Cancer, Hypoxia, and Metabolism (9) Monoclonal and Polyclonal Antibodies Research (9)

Frequent Co-Authors

BR
Brian Schwartz
4 joint publications
JO
Joachim von Pawel
3 joint publications
VE
Vera Hirsh
3 joint publications
AR
Armando Santoro
2 joint publications
JE
Jean Viallet
2 joint publications
GI
Giorgio V. Scagliotti
2 joint publications

Affiliations

University of Minnesota
US 1992 - 1986
AOL (United States)
US 2015 - 2015
Fairview Health Services
US 1986 - 1986
Royal Adelaide Hospital
AU 2000 - 2000
Memorial Sloan Kettering Cancer Center
US 1997 - 1997

External Profiles

OpenAlex Profile Search Semantic Scholar Google Scholar

Share Profile

Back to Researchers
Comparison Shortlist
0 journals
Est. APC Budget: $0
Compare Now